December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Myeloma Paper of the Day, November 19th, suggested by Robert Orlowski
Nov 19, 2024, 14:00

Myeloma Paper of the Day, November 19th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Early dFLC response by C1D7 (67.0% change, optimal sensitivity 87.5%, specificity 81.3%) may predict complete hematologic response and organ response in systemic AL amyloidosis and may allow for early modification of therapy.

Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis

Authors: Yang Liu, Jingyi Bi, Xuelin Dou, Nan Peng, Lei Wen, Yanqiu Zhao, Xiaojun Huang, Jin Lu.

Myeloma Paper of the Day, November 19th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.